Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience. - Yuen CA; Hsu JM; Van Besien K; Reshef R; Iwamoto FM; Haggiagi A; Liechty B; Zhang C; Wesley SF; Magge R (Journal of immunotherapy (Hagerstown, Md. : 1997), 2022)